Drugs / Dexelvucitabine
Dexelvucitabine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00040274 | — | HIV infectious disease | Pharmasset | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00300573 | Apr 2006 | HIV infectious disease | Incyte Corporation | Terminated | No outcome recorded |
Press releases naming this drug 10 releases
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dexelvucitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00300573 ↗ |
| Known as | Dexelvucitabina | ChEMBL registry synonym — accepted as the source's own label CHEMBL109831 ↗ |
| Known as | DFC | “Dexelvucitabine (DFC)” NCT00300573 ↗ |
| Known as | DPC 817 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00040274 ↗ |
| Known as | INCB-8721 | ChEMBL registry synonym — accepted as the source's own label CHEMBL109831 ↗ |
| Known as | Reverset | ChEMBL registry synonym — accepted as the source's own label CHEMBL109831 ↗ |
| Known as | YZ-817 | ChEMBL registry synonym — accepted as the source's own label CHEMBL109831 ↗ |
| Action | Inhibit | “nucleoside inhibitor of HIV Reverse Transcriptase” NCT00300573 ↗ |
| Modality | Small molecule | “investigation nucleoside analog reverse transcriptase inhibitor (NRTI)” NCT00300573 ↗ |
| Route | Oral | “Single Oral Doses” NCT00040274 ↗ |